{"hands_on_practices": [{"introduction": "To understand ferroptosis, we must first grasp the function of its master regulator, Glutathione Peroxidase 4 ($GPX4$). This exercise [@problem_id:2945363] invites you to model the protective action of $GPX4$ using the framework of Michaelis-Menten kinetics. By applying this classic biochemical model, you will calculate the direct quantitative impact of reduced enzyme efficiency on the steady-state levels of toxic phospholipid hydroperoxides, providing a solid foundation for why $GPX4$ inhibition is a potent trigger for ferroptosis.", "problem": "A central determinant of ferroptosis sensitivity is the cellular balance between the formation of phospholipid hydroperoxides and their enzymatic removal by Glutathione Peroxidase 4 ($GPX4$). Consider a well-mixed cell in which phospholipid hydroperoxides (denote concentration by $L$) are generated at a constant initiation rate $J_{\\mathrm{in}}$ due to iron-catalyzed lipid peroxidation, and are removed by $GPX4$ using reduced glutathione (GSH). At a fixed intracellular concentration of reduced glutathione (GSH), the $GPX4$-catalyzed reduction of phospholipid hydroperoxides can be treated as a single-substrate Michaelis–Menten reaction with an apparent maximal rate $V_{\\max}^{\\mathrm{app}}$ and an apparent Michaelis constant $K_{M}$ with respect to $L$. Assume the following:\n- The initiation rate is $J_{\\mathrm{in}} = 0.3\\ \\mathrm{\\mu M\\ s^{-1}}$.\n- At the given fixed GSH level, $V_{\\max}^{\\mathrm{app}} = 1.5\\ \\mathrm{\\mu M\\ s^{-1}}$ and $K_{M} = 6\\ \\mathrm{\\mu M}$.\n- The total cellular amount of $GPX4$ enzyme is constant.\n- The apparent maximal rate satisfies $V_{\\max}^{\\mathrm{app}} = k_{\\mathrm{cat}}^{\\mathrm{app}} [E]_{\\mathrm{tot}}$, so that a change in the catalytic turnover number $k_{\\mathrm{cat}}$ scales $V_{\\max}^{\\mathrm{app}}$ proportionally at fixed GSH and $[E]_{\\mathrm{tot}}$.\n- After a perturbation (for example, covalent inhibition), the catalytic turnover number $k_{\\mathrm{cat}}$ is reduced by $50$ percent, while $K_{M}$, GSH, and $J_{\\mathrm{in}}$ remain unchanged.\n- The system remains in the steady-state regime before and after the perturbation (that is, $V_{\\max}^{\\mathrm{app}}  J_{\\mathrm{in}}$ in both cases).\n\nUsing mass balance at steady state and Michaelis–Menten kinetics as the fundamental base, compute the new steady-state concentration of phospholipid hydroperoxides $L$ after the $50$ percent reduction in $k_{\\mathrm{cat}}$. Express the final concentration in micromolar (µM). Do not round if an exact value can be obtained.", "solution": "We begin from mass balance for the phospholipid hydroperoxide concentration, denoted by $L$:\n$$\n\\frac{dL}{dt} \\;=\\; J_{\\mathrm{in}} \\;-\\; v_{\\mathrm{GPX4}}(L).\n$$\nAt steady state, $\\frac{dL}{dt} = 0$, so\n$$\nJ_{\\mathrm{in}} \\;=\\; v_{\\mathrm{GPX4}}(L_{\\mathrm{ss}}).\n$$\n\nUnder fixed reduced glutathione (GSH), the GPX4 reaction can be modeled as a single-substrate Michaelis–Menten process with respect to $L$, characterized by an apparent maximal rate $V_{\\max}^{\\mathrm{app}}$ and an apparent Michaelis constant $K_{M}$. Thus,\n$$\nv_{\\mathrm{GPX4}}(L) \\;=\\; \\frac{V_{\\max}^{\\mathrm{app}}\\, L}{K_{M} + L}.\n$$\nImposing steady state gives\n$$\nJ_{\\mathrm{in}} \\;=\\; \\frac{V_{\\max}^{\\mathrm{app}}\\, L_{\\mathrm{ss}}}{K_{M} + L_{\\mathrm{ss}}}.\n$$\nSolving for $L_{\\mathrm{ss}}$,\n\\begin{align*}\nJ_{\\mathrm{in}}(K_{M} + L_{\\mathrm{ss}}) \\;=\\; V_{\\max}^{\\mathrm{app}} L_{\\mathrm{ss}}, \\\\\nJ_{\\mathrm{in}} K_{M} \\;=\\; L_{\\mathrm{ss}} \\bigl( V_{\\max}^{\\mathrm{app}} - J_{\\mathrm{in}} \\bigr), \\\\\nL_{\\mathrm{ss}} \\;=\\; \\frac{J_{\\mathrm{in}} K_{M}}{V_{\\max}^{\\mathrm{app}} - J_{\\mathrm{in}}}.\n\\end{align*}\nThis expression requires $V_{\\max}^{\\mathrm{app}}  J_{\\mathrm{in}}$, which is given.\n\nWe are asked for the new steady-state after a $50$ percent reduction in the catalytic turnover number $k_{\\mathrm{cat}}$. At fixed GSH and fixed $[E]_{\\mathrm{tot}}$, the apparent maximal rate obeys $V_{\\max}^{\\mathrm{app}} = k_{\\mathrm{cat}}^{\\mathrm{app}} [E]_{\\mathrm{tot}}$, so halving $k_{\\mathrm{cat}}$ halves $V_{\\max}^{\\mathrm{app}}$, while $K_{M}$ remains unchanged. Therefore,\n$$\nV_{\\max,\\ \\mathrm{new}}^{\\mathrm{app}} \\;=\\; \\frac{1}{2} V_{\\max}^{\\mathrm{app}}.\n$$\n\nWith the given numerical values $J_{\\mathrm{in}} = 0.3\\ \\mathrm{\\mu M\\ s^{-1}}$, $K_{M} = 6\\ \\mathrm{\\mu M}$, and initial $V_{\\max}^{\\mathrm{app}} = 1.5\\ \\mathrm{\\mu M\\ s^{-1}}$, the new apparent maximal rate is\n$$\nV_{\\max,\\ \\mathrm{new}}^{\\mathrm{app}} \\;=\\; \\frac{1}{2} \\times 1.5 \\;=\\; 0.75\\ \\mathrm{\\mu M\\ s^{-1}}.\n$$\nThe new steady-state concentration is then\n\\begin{align*}\nL_{\\mathrm{ss,new}} \\;=\\; \\frac{J_{\\mathrm{in}} K_{M}}{V_{\\max,\\ \\mathrm{new}}^{\\mathrm{app}} - J_{\\mathrm{in}}}\n\\;=\\; \\frac{(0.3)(6)}{0.75 - 0.3} \\\\\n=\\; \\frac{1.8}{0.45} \\\\\n=\\; 4.\n\\end{align*}\nHence, the new steady-state phospholipid hydroperoxide concentration is $4\\ \\mathrm{\\mu M}$. This increase reflects the reduced detoxification capacity relative to the ongoing initiation flux, illustrating how a decrease in GPX4 catalytic efficiency drives lipid hydroperoxide accumulation toward the ferroptotic regime.", "answer": "$$\\boxed{4}$$", "id": "2945363"}, {"introduction": "While the accumulation of lipid peroxides is the hallmark of ferroptosis, it is crucial to place this process within the broader landscape of regulated cell death. This practice [@problem_id:2945492] presents a conceptual challenge: to predict the effect of inhibitors for apoptosis, necroptosis, and pyroptosis on cells undergoing ferroptosis. This exercise will reinforce your understanding of the unique molecular machinery that defines each pathway and highlight the importance of pathway specificity when designing experiments.", "problem": "A researcher seeks to determine whether apoptosis, necroptosis, or pyroptosis execution machinery contributes to cell death when glutathione peroxidase $4$ (GPX$4$) activity is acutely inhibited. In a single human epithelial cell line maintained under iron-replete, normoxic conditions and standard culture medium, the researcher applies the covalent GPX$4$ inhibitor RSL$3$ to initiate death. In parallel conditions, the researcher co-treats with one of the following, each at a concentration verified to fully inhibit its intended target without affecting iron handling, lipid composition, antioxidant capacity, or radical chemistry: a pan-caspase inhibitor, a receptor-interacting serine/threonine-protein kinase $1$ (RIPK$1$) kinase inhibitor, or a gasdermin D pore blocker. Assume no off-target radical-trapping, no iron chelation, and no effects on glutathione synthesis or import. Which co-treatment, if any, is expected to prevent cell death triggered by RSL$3$ under these assumptions, and why?\n\nUse only the following fundamental base to reason: ferroptosis is defined as an iron-dependent, non-apoptotic form of regulated cell death driven by the accumulation of peroxidized phospholipids; GPX$4$ enzymatically reduces phospholipid hydroperoxides to alcohols using reduced glutathione; apoptosis requires caspase proteases for execution; necroptosis requires RIPK$1$/RIPK$3$/mixed lineage kinase domain-like protein signaling and membrane permeabilization by mixed lineage kinase domain-like protein; pyroptosis requires gasdermin D pore formation following inflammatory caspase cleavage. Do not assume crosstalk beyond these canonical definitions.\n\nOptions:\nA. The pan-caspase inhibitor will prevent death, because caspase activation is required downstream of lipid peroxidation to execute membrane permeabilization.\n\nB. The RIPK$1$ inhibitor will prevent death, because lipid peroxide accumulation engages necroptotic membrane rupture machinery.\n\nC. The gasdermin D pore blocker will prevent death, because RSL$3$-induced lipid peroxidation activates inflammatory caspases to cleave gasdermin D.\n\nD. None of these will prevent death; only interventions that suppress phospholipid peroxidation or iron-dependent radical propagation will block RSL$3$-induced death under these conditions.\n\nE. All of these will partially prevent death, because apoptosis, necroptosis, and pyroptosis share a common terminal membrane rupture mechanism engaged by lipid peroxides.", "solution": "The problem statement is first subjected to validation.\n\n**Step 1: Extract Givens**\n- **Process**: Cell death initiated by acute inhibition of glutathione peroxidase $4$ (GPX$4$) activity.\n- **Inducer**: RSL$3$, a covalent GPX$4$ inhibitor.\n- **System**: A single human epithelial cell line.\n- **Conditions**: Iron-replete, normoxic, standard culture medium.\n- **Co-treatments**:\n    1. Pan-caspase inhibitor.\n    2. Receptor-interacting serine/threonine-protein kinase $1$ ($RIPK1$) kinase inhibitor.\n    3. Gasdermin D ($GSDMD$) pore blocker.\n- **Assumptions**: Each inhibitor fully inhibits its target. Inhibitors do not affect iron handling, lipid composition, antioxidant capacity, or radical chemistry. No off-target radical-trapping, no iron chelation, no effects on glutathione synthesis or import.\n- **Fundamental Definitions**:\n    - **Ferroptosis**: an iron-dependent, non-apoptotic form of regulated cell death driven by the accumulation of peroxidized phospholipids.\n    - **GPX$4$ function**: enzymatically reduces phospholipid hydroperoxides to alcohols using reduced glutathione.\n    - **Apoptosis**: requires caspase proteases for execution.\n    - **Necroptosis**: requires $RIPK1$/$RIPK3$/$MLKL$ signaling and membrane permeabilization by $MLKL$.\n    - **Pyroptosis**: requires $GSDMD$ pore formation following inflammatory caspase cleavage.\n- **Constraint**: Do not assume crosstalk beyond these canonical definitions.\n- **Question**: Which co-treatment is expected to prevent cell death triggered by RSL$3$?\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is scientifically grounded, well-posed, and objective. It describes a standard experimental design in cell biology to dissect cell death pathways. The provided definitions for ferroptosis, apoptosis, necroptosis, and pyroptosis are accurate, albeit simplified, representations of the canonical pathways. The roles of GPX$4$ and RSL$3$ are correctly stated. The assumptions and constraints, such as \"no crosstalk\" and ideal inhibitor specificity, are typical for a theoretical problem designed to test fundamental knowledge by isolating core mechanisms. The problem is self-contained and free of contradictions or factual errors.\n\n**Step 3: Verdict and Action**\nThe problem is valid. A solution will be derived based on the provided givens and fundamental principles.\n\n**Derivation of Solution**\nThe central task is to identify the specific form of cell death induced by RSL$3$ under the given conditions and then determine if any of the proposed inhibitors can block it.\n\n1.  **Identify the mode of cell death**: The problem states that RSL$3$ is a covalent inhibitor of GPX$4$. According to the provided fundamental definitions, the function of GPX$4$ is to enzymatically reduce phospholipid hydroperoxides. Therefore, inhibition of GPX$4$ by RSL$3$ will lead to a failure in this detoxification process, resulting in the \"accumulation of peroxidized phospholipids\". The problem also defines ferroptosis as an \"iron-dependent... form of regulated cell death driven by the accumulation of peroxidized phospholipids\". Since the cells are maintained in iron-replete conditions, the cell death initiated by RSL$3$ is, by definition, ferroptosis.\n\n2.  **Evaluate the effect of the inhibitors on ferroptosis**: The problem requires evaluating each inhibitor based on the canonical pathway definitions, with the strict constraint of \"no crosstalk\".\n\n    -   **Pan-caspase inhibitor**: This inhibitor targets caspases. Caspases are defined as the executioner machinery for apoptosis. Ferroptosis is explicitly defined as \"non-apoptotic\". Therefore, based on the provided framework, inhibiting caspases will not affect the execution of ferroptosis.\n\n    -   **$RIPK1$ kinase inhibitor**: This inhibitor targets $RIPK1$ kinase activity, which is a key initiator of the necroptosis pathway, defined as requiring \"$RIPK1$/$RIPK3$/$MLKL$ signaling\". Ferroptosis is a distinct pathway. With the \"no crosstalk\" constraint, there is no basis to assume that the ferroptotic process engages the $RIPK1$-dependent necroptotic machinery. Thus, inhibiting $RIPK1$ will not prevent ferroptosis.\n\n    -   **$GSDMD$ pore blocker**: This inhibitor targets $GSDMD$ pores, the final execution step of pyroptosis. Pyroptosis is defined as requiring \"$GSDMD$ pore formation following inflammatory caspase cleavage\". As with the other pathways, there is no defined link between the accumulation of peroxidized phospholipids in ferroptosis and the activation of the pyroptotic cascade. Therefore, blocking $GSDMD$ pores will be ineffective.\n\n3.  **Conclusion**: Since RSL$3$-induced death is ferroptosis, and the inhibitors target the distinct pathways of apoptosis, necroptosis, and pyroptosis, none of these co-treatments will prevent cell death under the strict \"no crosstalk\" assumption. Cell death could only be prevented by interventions that directly address the core mechanism of ferroptosis, namely the iron-dependent accumulation of lipid peroxides. This would involve either blocking the generation of lipid peroxides (e.g., with a lipid-soluble radical-trapping antioxidant) or removing the iron required for their propagation (e.g., with an iron chelator). The problem explicitly states the tested inhibitors lack these properties.\n\n**Evaluation of Options**\n\n**A. The pan-caspase inhibitor will prevent death, because caspase activation is required downstream of lipid peroxidation to execute membrane permeabilization.**\nThis statement is **Incorrect**. Ferroptosis is defined as non-apoptotic. Apoptosis requires caspases. Therefore, caspases are not involved in ferroptosis according to the problem's axioms.\n\n**B. The RIPK$1$ inhibitor will prevent death, because lipid peroxide accumulation engages necroptotic membrane rupture machinery.**\nThis statement is **Incorrect**. This presumes a crosstalk between ferroptosis and necroptosis, where lipid peroxides trigger the $RIPK1$-dependent pathway. Such crosstalk is explicitly forbidden by the problem's constraints.\n\n**C. The gasdermin D pore blocker will prevent death, because RSL$3$-induced lipid peroxidation activates inflammatory caspases to cleave gasdermin D.**\nThis statement is **Incorrect**. Similar to option B, this assumes a disallowed crosstalk between ferroptosis and pyroptosis. The canonical definition of ferroptosis does not involve activation of inflammatory caspases or gasdermin D.\n\n**D. None of these will prevent death; only interventions that suppress phospholipid peroxidation or iron-dependent radical propagation will block RSL$3$-induced death under these conditions.**\nThis statement is **Correct**. As deduced above, the initiated cell death is ferroptosis. The inhibitors for apoptosis, necroptosis, and pyroptosis do not affect the ferroptotic pathway based on the canonical definitions provided. The statement correctly identifies that blocking ferroptosis requires targeting its core mechanism: either the lipid peroxidation itself or the iron that catalyzes it.\n\n**E. All of these will partially prevent death, because apoptosis, necroptosis, and pyroptosis share a common terminal membrane rupture mechanism engaged by lipid peroxides.**\nThis statement is **Incorrect**. The premise is factually wrong. Apoptosis (via caspases), necroptosis (via $MLKL$ pores), and pyroptosis (via $GSDMD$ pores) utilize distinct, non-common terminal membrane permeabilization mechanisms.", "answer": "$$\\boxed{D}$$", "id": "2945492"}, {"introduction": "Understanding ferroptosis at the molecular level is the first step; the next is recognizing its signature in experimental data. This practice [@problem_id:2945422] places you in the role of an experimentalist interpreting a common metabolic phenotype—a shift from oxidative phosphorylation to glycolysis—observed after inducing ferroptosis. Your task is to critically assess this observation and devise a strategy to distinguish true metabolic reprogramming from the consequences of ferroptotic membrane damage, honing your skills in experimental design and data interpretation.", "problem": "A researcher treats cultured mammalian cells with the small-molecule glutathione peroxidase $4$ (GPX$4$) inhibitor RSL$3$ under conditions that preserve adherence and comparable cell numbers during the assay window. Using a Seahorse extracellular flux analyzer, the researcher observes a pronounced decrease in oxygen consumption rate (OCR) and a concomitant increase in extracellular acidification rate (ECAR) shortly after RSL$3$ addition. The medium composition, buffering capacity, and substrate availability are held constant across conditions.\n\nStarting from first principles, recall that mitochondrial electron transport consumes molecular oxygen $\\mathrm{O_2}$ and establishes a proton-motive force used for adenosine triphosphate (ATP) synthesis, whereas glycolysis converts glucose to lactate with net production of acid equivalents that are exported with monocarboxylate transport. Also recall that GPX$4$ reduces phospholipid hydroperoxides to alcohols using reduced glutathione, limiting iron-dependent lipid radical chain reactions in polyunsaturated phospholipids; inhibition of GPX$4$ allows phospholipid hydroperoxides to accumulate, a hallmark of ferroptosis, which can compromise both mitochondrial function and plasma membrane integrity.\n\nGiven only the Seahorse readout (decreased OCR, increased ECAR) after RSL$3$, which of the following interpretations and orthogonal readouts best discriminates adaptive metabolic rewiring toward glycolysis from ferroptotic membrane damage as the proximate cause of the flux changes?\n\nA. Conclude an adaptive shift to glycolysis. As an orthogonal readout, add $2$-deoxyglucose to confirm that ECAR falls, thereby validating glycolytic rewiring as the cause of the Seahorse phenotype.\n\nB. Do not conclude solely metabolic rewiring because GPX$4$ inhibition can trigger phospholipid peroxidation that impairs mitochondria and compromises membranes, secondarily elevating glycolytic flux or causing acid-equivalent leakage. As an orthogonal readout, quantify lipid peroxidation with C$11$-BODIPY $581/591$ oxidation and targeted phosphatidylethanolamine hydroperoxides by liquid chromatography–mass spectrometry (LC–MS), and test rescue with ferrostatin-$1$; reversal of both lipid peroxidation and the Seahorse changes by ferrostatin-$1$ supports ferroptotic membrane damage as the driver.\n\nC. Conclude caspase-dependent apoptosis. As an orthogonal readout, measure caspase-$3/7$ activity; if elevated, it explains the Seahorse phenotype as apoptotic remodeling rather than ferroptosis.\n\nD. Conclude mitochondrial uncoupling. As an orthogonal readout, perform a mitochondrial stress test with oligomycin and FCCP to quantify spare respiratory capacity; if spare capacity is low, this confirms uncoupling as the cause and excludes ferroptosis.\n\nE. Conclude iron-independent metabolic stress. As an orthogonal readout, measure total cellular iron by a colorimetric assay; if unchanged, the Seahorse phenotype must reflect glycolytic rewiring rather than membrane damage.", "solution": "The problem requires a critical evaluation of experimental interpretations and proposed follow-up experiments to distinguish between two potential causes for an observed metabolic phenotype. The phenotype, observed after treating mammalian cells with the glutathione peroxidase $4$ (GPX$4$) inhibitor RSL$3$, is a decrease in the oxygen consumption rate (OCR) and a simultaneous increase in the extracellular acidification rate (ECAR). This pattern is classically associated with a shift from oxidative phosphorylation to glycolysis. The core of the problem is to determine whether this shift is an adaptive metabolic reprogramming or a consequence of cellular damage, specifically ferroptotic membrane damage, which is the known mechanism of RSL$3$.\n\nFirst, a rigorous analysis of the given information is required.\nThe treatment is with RSL$3$, a specific and direct covalent inhibitor of GPX$4$. The function of GPX$4$ is to reduce phospholipid hydroperoxides ($\\text{PL-OOH}$) to the corresponding phospholipid alcohols ($\\text{PL-OH}$) using reduced glutathione ($\\text{GSH}$) as a cofactor.\n$$ \\text{PL-OOH} + 2 \\, \\text{GSH} \\xrightarrow{\\text{GPX4}} \\text{PL-OH} + \\text{GSSG} + \\text{H}_2\\text{O} $$\nInhibition of GPX$4$ by RSL$3$ leads to the accumulation of $\\text{PL-OOH}$. In the presence of labile, redox-active iron ($\\mathrm{Fe}^{2+}$), these lipid hydroperoxides can initiate and propagate lipid radical chain reactions, a process termed ferroptosis. This rampant lipid peroxidation can cause severe damage to cellular membranes, including the plasma membrane and mitochondrial membranes.\n\nThe observed Seahorse phenotype is:\n1.  Decreased OCR: The oxygen consumption rate is a direct measure of mitochondrial electron transport chain (ETC) activity. A decrease signifies impaired mitochondrial respiration. This could be due to damage to ETC complexes, disruption of the mitochondrial membrane potential, or depletion of substrates for the tricarboxylic acid (TCA) cycle. Lipid peroxidation of mitochondrial membranes is a well-established cause of such damage.\n2.  Increased ECAR: The extracellular acidification rate primarily reflects the efflux of lactic acid, the end product of glycolysis. An increase indicates an elevated rate of glycolysis.\n\nTwo hypotheses are proposed to explain this phenotype:\nHypothesis $1$: Adaptive metabolic rewiring. The cell, under stress from RSL$3$, actively and in a regulated manner, shifts its energy production strategy from oxidative phosphorylation to glycolysis.\nHypothesis $2$: Ferroptotic membrane damage. The primary event is lipid peroxidation, which directly damages mitochondria, causing the OCR to drop. The increase in ECAR is a secondary effect, either a compensatory (\"Pasteur-like\") effect to maintain ATP production or a consequence of plasma membrane damage leading to leakage of acidic equivalents.\n\nThe task is to identify the best experimental strategy among the given options to discriminate between these two hypotheses.\n\nLet us evaluate each option.\n\nA. Conclude an adaptive shift to glycolysis. As an orthogonal readout, add $2$-deoxyglucose to confirm that ECAR falls, thereby validating glycolytic rewiring as the cause of the Seahorse phenotype.\nThis option is logically flawed. It begins with a premature conclusion, dismissing the possibility of damage-induced effects without evidence. The proposed experiment, using $2$-deoxyglucose ($2$-DG), a hexokinase inhibitor, only serves to confirm that the observed ECAR is indeed a product of glycolysis. This is almost certainly true and does not provide any discriminatory information. It fails to address the central question: *why* did the glycolytic rate increase? Is it an adaptive program or a compensatory response to mitochondrial failure? This experiment does not distinguish between these two possibilities. Therefore, this option is incorrect.\n\nB. Do not conclude solely metabolic rewiring because GPX$4$ inhibition can trigger phospholipid peroxidation that impairs mitochondria and compromises membranes, secondarily elevating glycolytic flux or causing acid-equivalent leakage. As an orthogonal readout, quantify lipid peroxidation with C$11$-BODIPY $581/591$ oxidation and targeted phosphatidylethanolamine hydroperoxides by liquid chromatography–mass spectrometry (LC–MS), and test rescue with ferrostatin-$1$; reversal of both lipid peroxidation and the Seahorse changes by ferrostatin-$1$ supports ferroptotic membrane damage as the driver.\nThis option presents a comprehensive and scientifically rigorous approach. It correctly acknowledges the ambiguity of the initial Seahorse data. The proposed orthogonal readouts are highly specific and address the core mechanism of RSL$3$.\n1.  Direct measurement of lipid peroxidation: Using the fluorescent probe C$11$-BODIPY $581/591$ and quantitative LC–MS analysis of specific phospholipid hydroperoxides (like PE-OOH) directly tests for the molecular hallmark of ferroptosis. This would confirm that the stimulus (RSL$3$) is having its expected primary effect.\n2.  Pharmacological rescue experiment: Ferrostatin-$1$ is a specific inhibitor of ferroptosis that acts by trapping lipid radicals, thereby terminating the chain reaction of lipid peroxidation. If ferrostatin-$1$ co-treatment prevents both the RSL$3$-induced lipid peroxidation *and* the observed Seahorse phenotype ($\\downarrow$OCR, $\\uparrow$ECAR), it establishes a causal link between ferroptotic membrane damage and the metabolic changes. This directly tests the \"ferroptotic damage\" hypothesis. If the Seahorse phenotype occurred independently of lipid peroxidation (as in a purely adaptive response), ferrostatin-$1$ would not rescue it. This strategy provides the necessary evidence to discriminate between the two hypotheses. Therefore, this option is correct.\n\nC. Conclude caspase-dependent apoptosis. As an orthogonal readout, measure caspase-$3/7$ activity; if elevated, it explains the Seahorse phenotype as apoptotic remodeling rather than ferroptosis.\nThis option is misguided. RSL$3$ is a canonical inducer of ferroptosis, which is defined as a caspase-independent form of regulated cell death. While some crosstalk can exist, proposing apoptosis as the primary mechanism is contrary to established knowledge. The experiment to measure caspase-$3/7$ activity is useful for ruling out apoptosis but is not the most pertinent experiment to investigate the mechanism of RSL$3$-induced metabolic changes. This option incorrectly shifts the focus to a less likely cell death pathway instead of dissecting the consequences of the known pathway, ferroptosis. Therefore, this option is incorrect.\n\nD. Conclude mitochondrial uncoupling. As an orthogonal readout, perform a mitochondrial stress test with oligomycin and FCCP to quantify spare respiratory capacity; if spare capacity is low, this confirms uncoupling as the cause and excludes ferroptosis.\nThe initial interpretation is factually wrong. Mitochondrial uncoupling, caused by agents like FCCP (carbonyl cyanide-$p$-trifluoromethoxyphenylhydrazone), dissipates the proton gradient, forcing the ETC to work at its maximum rate to compensate. This leads to an *increase* in OCR, not a decrease. The observed decrease in OCR points towards inhibition or damage to the ETC, not uncoupling. While a mitochondrial stress test would be informative and would likely reveal a loss of basal and maximal respiration (hence low spare capacity) due to mitochondrial damage from lipid peroxidation, the premise that this confirms \"uncoupling\" is incorrect. Furthermore, this mitochondrial damage is a predicted consequence of ferroptosis, so demonstrating it does not exclude ferroptosis; it is consistent with it. This option is based on a flawed premise. Therefore, this option is incorrect.\n\nE. Conclude iron-independent metabolic stress. As an orthogonal readout, measure total cellular iron by a colorimetric assay; if unchanged, the Seahorse phenotype must reflect glycolytic rewiring rather than membrane damage.\nThis option is based on a misunderstanding of the role of iron in ferroptosis. Ferroptosis is iron-*dependent*, not iron-*driven* in the sense of requiring an increase in total iron content. The process relies on a pre-existing pool of labile, catalytically active iron ($\\mathrm{Fe}^{2+}$) within the cell. The total cellular iron content is not expected to change upon acute induction of ferroptosis by RSL$3$. Finding that total iron is unchanged does not rule out ferroptosis. The conclusion that this finding would imply the phenotype is due to glycolytic rewiring is a non sequitur. Causal links are not established by this experiment. Therefore, this option is incorrect.\n\nIn summary, only option B outlines a logically sound and experimentally robust strategy to resolve the ambiguity presented in the problem statement. It correctly identifies the primary mechanism of the inducing agent and proposes specific experiments (direct measurement of the primary effect and a targeted rescue experiment) to establish a causal link to the downstream observations.", "answer": "$$\\boxed{B}$$", "id": "2945422"}]}